阿奇霉素加用化痰止咳合剂及止咳贴治疗肺炎支原体肺炎临床价值

王新蓉 王书乐 范炜方 高吟

[摘要]目的探討阿奇霉素加用化痰止咳合剂及止咳贴治疗肺炎支原体肺炎的临床价值。方法选取2018年1月至2020年1月无锡市中医医院儿科100例肺炎支原体肺炎住院患儿，使用随机数字表法分为观察组与对照组，每组各50例，观察组给予阿奇霉素加用我院自制中成药化痰止咳合剂及止咳贴治疗，对照组单用阿奇霉素治疗。观察两组热退时间、止咳时间、啰音消失时间、住院天数、疗效、不良反应及炎症因子水平[血清 C-反应蛋白（CRP）、白细胞介素-17（IL-17）、降钙素原（PCT）]。结果观察组退热、止咳、肺部啰音消失时间及住院天数短于对照组，差异有统计学意义（P<0.05）;观察组总有效率高于对照组，差异有统计学意义（ P <0.05）;观察组不良反应总发生率高于对照组，差异无统计学意义（P>0.05），治疗前两组 CRP、PCT 和 IL-17比较，差异无统计学意义（P>0.05），治疗后，两组 CRP、PCT 和 IL-17均低于治疗前，且观察组指标优于对照组，差异有统计学意义（P <0.05）。结论阿奇霉素加用化痰止咳合剂及止咳贴治疗肺炎支原体肺炎有良好的临床效果，且未增加不良反应。

[关键词]化痰止咳合剂;阿奇霉素;肺炎支原体肺炎;止咳贴

[中图分类号] R725.6  [文献标识码] A   [文章编号]2095-0616（2022）09-0103-04

Clinical value of azithromycin combined with HuatanZhike mixture and Zhike plaster in the treatment of mycoplasma pneumoniae pneumonia

WANG  Xinrong    WANG  Shule    FAN  Weifang    GAO  Yin

1. Department of Pediatrics， Wuxi Traditional Chinese Medicine Hospital， Jiangsu， Wuxi 214071， China;2. Central Laboratory， Wuxi Traditional Chinese Medicine Hospital， Jiangsu， Wuxi 214071， China;3. Department of Rehabilitation， Wuxi Traditional Chinese Medicine Hospital， Jiangsu， Wuxi 214071， China;4. Department of Clinical Laboratory， Wuxi Traditional Chinese Medicine Hospital， Jiangsu， Wuxi 214071， China

[Abstract] Objective To investigate the clinical value of azithromycin combined with HuatanZhike mixture and Zhike plaster in the treatment of mycoplasma pneumoniae pneumonia. Methods A total of 100 inpatients with mycoplasma pneumoniae pneumonia in the Department of Pediatrics in Wuxi Traditional Chinese Medicine Hospital from January 2018 to January 2020 were selected， and they were divided into the observation group and the control group according to the random number table method， with 50 cases in each group. The observation group was treated with azithromycin，and combined with the self-made Chinese patent medicine named HuatanZhike mixture and Zhike plaster， while the control group was only treated with azithromycin. The time of fever regression， cough relief， disappearance of rales， hospitalization days， curative efficacy， adverse reactions （ADRs） and level of inflammatory factors （serum C-reactive protein [CRP]， interleukin-17[IL-17] and calcitonin original [PCT]） were observed in the two groups. Results The disappearance time of fever， relieving cough， pulmonary rales and the length of hospital stay in the observation group were shorter than those in the control group， and the differences were statistically significant （P <0.05）; the total effective rate in the observation group was higher than that in the control group， and the difference was statistically significant （P <0.05）; the total incidence of adverse reactions in the observation group was higher than that in the control group， and the difference was not statistically significant （P >0.05）. Before treatment， there were no significant differences in CRP， PCT and IL-17 between the two groups （P >0.05）. After treatment， CRP， PCT and IL-17 in the two groups were lower than those before treatment， and the indexes in the observation group were better than those in thecontrol group， and the difference were statistically significant （P <0.05）. Conclusion Azithromycin combined with HuatanZhike mixture and Zhike plaster has a good clinical efficacy in the treatment of mycoplasma pneumoniae pneumonia， without increasing ADRs simultaneously.

[Key words] HuatanZhike mixture; Azithromycin; Mycoplasma pneumoniae pneumonia; Zhike plaster

肺炎支原体是介于细菌和病毒间的自行繁殖的病原体，可感染儿童呼吸道导致非典型病原体肺炎，其感染在儿童中具有较高的发病率，且发病率呈现低龄化的趋势。肺炎支原体肺炎在非流行年份占小儿社区获得性肺炎的10%～20%，流行年份则高达30%以上[1]。易忽视或误诊患儿肺外损害的情况。……